Cargando…
Confidence in Biosimilar Drugs is Not Much Improved by Framing Them as the “Gold” Alternative Treatment Option to Bio-originators
INTRODUCTION: Biosimilar drugs have promising potential to provide substantial health, financial, and access benefits to patients and the entire healthcare system. However, skepticism remains a hurdle to their incorporation into clinical practice. METHODS: In this study, we evaluated how confidence...
Autores principales: | Hrin, Matthew L., Feldman, Steven R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322197/ https://www.ncbi.nlm.nih.gov/pubmed/33956326 http://dx.doi.org/10.1007/s13555-021-00542-8 |
Ejemplares similares
-
Reassurance Techniques Do Not Significantly Impact Confidence in Biosimilars for Psoriasis: A Survey of a Convenience Sample of Individuals with Self-Identified Psoriasis
por: Hrin, Matthew L., et al.
Publicado: (2022) -
Why are biosimilars much more complex than generics?
por: Pagani, Eduardo
Publicado: (2019) -
Do confidence ratings prime confidence?
por: Double, Kit S., et al.
Publicado: (2019) -
Biosimilar Naming Conventions: Pharmacist Perceptions and Impact on Confidence in Dispensing Biologics
por: Tomaszewski, Daniel
Publicado: (2016) -
Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)